Reply by Authors

Abstract

No AccessJournal of UrologyLetter to the Editor/Errata1 Mar 2018Reply by Authors View All Author Informationhttps://doi.org/10.1016/j.juro.2017.09.159AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Reply by Authors." The Journal of Urology, 199(3), pp. 855–856 References 1 : Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol2015; 26: 812. Google Scholar 2 : Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol2016; 34: 3119. Google Scholar 3 : Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet2016; 387: 1909. Google Scholar 4 : Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol2016; 17: 1590. Google Scholar 5 : PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin Cancer Res2017; 23: 4938. Google Scholar 6 : Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol2017; 10.1097/PAI.0000000000000531. Crossref, Google Scholar 7 : PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol2017; 12: 208. Google Scholar © 2018 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 199Issue 3March 2018Page: 855-856 Advertisement Copyright & Permissions© 2018 by American Urological Association Education and Research, Inc.MetricsAuthor Information Expand All Advertisement PDF downloadLoading ...